Potential biomarkers have also been proposed to predict patient response to immunotherapies such as expression of ligands and clonal tumor neoantigens such as PD-L1, PD-1, CTLA-4, beta-2-microglobulin (β2M) and class-I MHC (HLA-I) in determination of efficacy of checkpoint blockers [9] and expression of CD58 as a predictor of response to CD19 CAR T cell therapy [10]. Here, B2M is linked to neoplasm.